Important Information About Paxlovid
Paxlovid (nirmatrelvir/PF-07321332 and ritonavir) is an oral antiviral drug that should be initiated as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset. Paxlovid is available for patients by prescription only. Prescriptions can be obtained from your health care provider or through the Test to Treat program.
Paxlovid is authorized for the treatment of mild to moderate COVID-19 in adult and pediatric patients age 12 years and older weighing at least 40 kg, with a positive SARS-CoV-2 test, who are at high risk for progressing to severe COVID-19, including hospitalization or death. Please see the Eligibility Screening Checklist for additional details.
Paxlovid is available in two package presentations:*
- Paxlovid Standard Dose that includes 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) taken together twice daily for 5 days.
- Paxlovid Renal Dose for people with moderate renal impairment (eGFR > 30 mL/min to < 60 mL/min) that includes 150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) taken together twice daily for 5 days. Paxlovid is not recommended for people with severe renal impairment.
*The standard dose pack may be modified for renal dosing. Instructions can be found on page two of the Paxlovid Dear Healthcare Provider Letter.
Emergency Use Authorization of Paxlovid
On April 14, 2022, the U.S. Food and Drug Administration (FDA) revised the original December 22, 2021 Emergency Use Authorization (EUA) for the COVID-19 oral antiviral therapeutic Paxlovid to authorize an additional dose pack presentation with appropriate dosing for patients with moderate renal impairment within the scope of the EUA.
Paxlovid is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19. Paxlovid is not a substitute for vaccination in individuals for whom COVID-19 vaccination and a booster dose are recommended. There are known drug interactions with Paxlovid, see the Drug Interaction Checker for more information.